In Depth 19 Jun 2024
MASH candidates make a splash after first drug approval
The first drug to treat MASH, a potentially life-threatening liver disease, was approved this year. More recent advancements bring hope to patients.
About
Having completed a master’s programme in International Journalism from Cardiff University in 2022, I have written about various subjects including culture, politics, social justice, mental health, LGBTQ+ issues and gender. My undergraduate degree in life sciences has equipped me to explore my passion for reporting on health, science and the environment. When I’m not transcribing interviews and fretting about deadlines, I like to spend my time reading, watching movies, and making lousy mixtapes for a potential side career in rap music.
Articles by Roohi Mariam Peter
In Depth 17 Jun 2024
Moving with the times: biopharma royalty deals on the rise
A spate of royalty deals are changing the way certain biotechs press ahead. This trend seems to be an alternative to traditional biopharma fundraising.
In Depth 10 Jun 2024
ASCO 2024: The latest advances in oncology clinical trials
Biotechs from all over the country as well as other parts of the world showcased recent pipeline advancements in oncology clinical trials at ASCO 2024.
In Depth 6 Jun 2024
CRISPR: A promising path to treating blindness
Rigorous research, which has been going on for more than a decade now, suggests that CRISPR could treat genetic diseases including blindness.
In Depth 5 Jun 2024
Evolving standards of care: new treatments for cervical cancer
New treatments for cervical cancer aim to broaden therapeutic options, and improve current standards of care for patients.
Best in Biotech 31 May 2024
Biotech career fairs in the U.S. you don’t want to miss
Biotech career fairs are held to connect talent with professionals and recruiters. Here are six popular events that take place annually in the U.S.
ADVERTISEMENT
ADVERTISEMENT
In Depth 30 May 2024
Covalent biologics: a new class of drugs on the horizon
The field of covalent biologics has made headway recently, as the only biotech in the space has bagged $100 million to move its pipeline to the clinic.
In Depth 23 May 2024
Is prime editing ready for prime time?
Prime editing, a more advanced version of CRISPR/Cas9 technology, has been greenlit by the FDA to begin the first-ever clinical trial for this technology.
In Depth 22 May 2024
The undruggable cancer target: KRAS inhibitors move ahead in the clinic
Uncover the promise of KRAS inhibitors in cancer treatment, as evidenced by a $200 million investment in BridgeBio’s spinout.
In Depth 15 May 2024
Drugs for IgA nephropathy on the rise in the clinic
As we observed IgA Nephropathy Awareness Day on May 14th, let us take a look at ongoing clinical trials for drugs that aim to make patient lives better.
In Depth 9 May 2024
BTK inhibitors: can these drugs tackle cancer and autoimmunity?
BTK inhibitors were first approved over a decade ago to treat a rare blood cancer. Now, they are in the running to treat a host of autoimmune diseases.
In Depth 6 May 2024
The rise of Spain: A key player in global clinical trials
Spain has climbed the research and development ladder in recent years, and has made it to the top as one of the world leaders in the life science industry.
ADVERTISEMENT
